ZANTE GREG (Chief Financial Officer) sold 4.8% of their position (7.50K shares) of VIKING THERAPEUTICS, INC. on the open market
Open‑market sale worth $150.0K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/18/2023ACC: 0001209191-23-024722
Officer· Chief Financial Officer
Since Jan 2021
-7.50K
Net shares
Net seller
$150.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
7.50K acquired · 15K disposed
Non-Derivative Transactions2
Common Stock, par value $0.00001 per share
Direct
Shares
+7.50K
Price / share
$13.07
Trade value
$98.03K
% of position
5.0%
4/17/2023
149.28K→156.78K
Common Stock, par value $0.00001 per share
Direct
Shares
−7.50K
Price / share
$20.00
Trade value
$150K
% of position
4.8%
4/17/2023
156.78K→149.28K
Total
Net shares
+0.00
Net value
-$51.98K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share Direct | 4/17/2023 | M · Option Exercise | +7.50K | $13.07 | $98.03K | 5.0% | 149.28K | 156.78K |
| Common Stock, par value $0.00001 per share Direct | 4/17/2023 | S · Sale | −7.50K | $20.00 | $150K | 4.8% | 156.78K | 149.28K |
| Total | +0.00 | -$51.98K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
7.50K shares
Shares
−7.50K
Strike price
13.07
Held after
0.00
Exercisable
—
4/17/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock7.50K shares | 4/17/2023 | M · Option Exercise | −7.50K | 13.07 | — | 0.00 |